Personal information

Immunology, Cancer Immunotherapy, Pathogen Recognition, T Cell, MHC, Neoantigen
China

Biography

Dr. Bai was graduated from Wuhan University, China. He is broadly interested in studying how T-cells recognized cancer antigens and how antigen recognition manipulates T cell signaling in order to control T cell function and fate, by using structural, biochemical and bioinformatic approaches. His goals are to develop tools to predict cancer neoantigen immunogenicity based on neoantigen immunogenic properties and discover specific receptors to target them.

Activities

Education and qualifications (1)

Wuhan University: Wuhan, Hubei, CN

2017-09-01 to 2021-07-31 | Ph.D. (College of Life Sciences)
Education
Source: Self-asserted source
Peng Bai

Works (9)

Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in rats

Journal of Clinical Investigation
2025-01-02 | Journal article
Contributors: Xinxia Zhu; Russell Potterfield; Kenneth A. Gruber; Emma Zhang; Samuel D. Newton; Mason A. Norgard; Peter R. Levasseur; Peng Bai; Xu Chen; Qingyang Gu et al.
Source: check_circle
Crossref

Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss

2024-09-19 | Preprint
Contributors: Xinxia Zhu; Russell Potterfield; Kenneth A. Gruber; Emma Zhang; Samuel Newton; Mason A. Norgard; Peter R. Levasseur; Peng Bai; Xu Chen; Qingyang Gu et al.
Source: check_circle
Crossref

Old concepts, new tricks: How peptide vaccines are reshaping cancer immunotherapy?

International journal of biological macromolecules
2024-09-11 | Journal article
Contributors: Liu Q; Wu P; Lei J; Bai P; Zhong P; Yang M; Wei P
Source: Self-asserted source
Peng Bai

NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy

Frontiers in Immunology
2021-04 | Journal article
Part of ISSN: 1664-3224
Contributors: Jiaqi Xia; Peng Bai; Weiliang Fan; Qiming Li; Yongzheng Li; Dehe Wang; Lei Yin; Yu Zhou
Source: Self-asserted source
Peng Bai via Crossref Metadata Search
grade
Preferred source (of 2)‎

Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation.

Science China. Life sciences
2021-03 | Journal article
Contributors: Bai P; Zhou Q; Wei P; Bai H; Chan SK; Kappler JW; Marrack P; Yin L
Source: Self-asserted source
Peng Bai via Europe PubMed Central

Antiviral peptides targeting the helicase activity of enterovirus nonstructural protein 2C.

Journal of virology
2021-03-31 | Journal article
Source: Self-asserted source
Peng Bai

Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy

OncoImmunology
2021-01 | Journal article
Contributors: Peng Bai; Yongzheng Li; Qiuping Zhou; Jiaqi Xia; Peng-Cheng Wei; Hexiang Deng; Min Wu; Sanny K. Chan; John W. Kappler; Yu Zhou et al.
Source: check_circle
Crossref

Ebola virus VP35 has novel NTPase and helicase-like activities

Nucleic Acids Research
2019-05-08 | Journal article
Part of ISSN: 0305-1048
Contributors: Ting Shu; Tianyu Gan; Peng Bai; Xiaotong Wang; Qi Qian; Hui Zhou; Qi Cheng; Yang Qiu; Lei Yin; Jin Zhong et al.
Source: Self-asserted source
Peng Bai via Crossref Metadata Search
grade
Preferred source (of 2)‎

USP2a Supports Metastasis by Tuning TGF-β Signaling

Cell Reports
2018 | Journal article
EID:

2-s2.0-85042589983

Part of ISSN: 22111247
Contributors: Zhao, Y.; Wang, X.; Wang, Q.; Deng, Y.; Li, K.; Zhang, M.; Zhang, Q.; Zhou, J.; Wang, H.-Y.; Bai, P. et al.
Source: Self-asserted source
Peng Bai via Scopus - Elsevier
grade
Preferred source (of 2)‎

Peer review (1 review for 1 publication/grant)

Review activity for Signal transduction and targeted therapy. (1)